Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's Jelly for Knee Osteoarthritis
NCT04719793Phase 1Unknown
- Sponsor
- BioIntegrate
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of GeneXSTEM in knee osteoarthritis (OA), sponsored by BioIntegrate. Primary endpoint: Treatment-emergent adverse effects at 1 year. Status: unknown.
02
Drugs
GeneXSTEM
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04719793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719793.